Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Dec;3(6):983–990. doi: 10.1111/j.1365-2125.1976.tb00347.x

Plasma dopa concentrations after different preparations of levodopa in normal subjects

J G L Morris, R L Parsons, J R Trounce, M J Groves
PMCID: PMC1428975  PMID: 22216519

Abstract

1 The concurrent administration of levodopa with a decarboxylase inhibitor produced a plasma concentration/time curve comparable with 1/4 to 1/5 of the dose of levodopa given alone.

2 There was no evidence to suggest that the decarboxylase inhibitor slowed the rate of elimination of levodopa from plasma.

3 Metoclopramide (Maxolon) increased the rate of levodopa absorption. Higher plasma concentrations of levodopa during the first 2 h after dosing were followed by lower plasma concentrations during the third and fourth hours. The amount of levodopa absorbed after Larodopa as indicated by the AUC was not altered by adding metoclopramide.

4 None of the current preparations of levodopa produced sustained plasma concentrations.

5 In vitro testing confirmed that Brocadopa Temtabs tablets disintegrate and dissolve slowly. In vivo, Brocadopa Temtabs behaved as a slow release preparation but it did not produce sustained plasma concentrations of levodopa.

Full text

PDF
987

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adibi S. A., Gray S. J. Intestinal absorption of essential amino acids in man. Gastroenterology. 1967 May;52(5):837–845. [PubMed] [Google Scholar]
  2. Bianchine J. R., Messiha F. S., Hsu T. H. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):584–594. doi: 10.1002/cpt1972134584. [DOI] [PubMed] [Google Scholar]
  3. Calne D. B., Reid J. L., Vakil S. D., Rao S., Petrie A., Pallis C. A., Gawler J., Thomas P. K., Hilson A. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J. 1971 Sep 25;3(5777):729–732. doi: 10.1136/bmj.3.5777.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Casteels-Van Daele M., Jaeken J., Van der Schueren P., Van den Bon P. Dystonic reactions in children caused by metoclopramide. Arch Dis Child. 1970 Feb;45(239):130–133. doi: 10.1136/adc.45.239.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Castleden C. M., Kaye C. M., Parsons R. L. The effect of age on plasma levels of propranolol and practolol in man. Br J Clin Pharmacol. 1975 Aug;2(4):303–306. doi: 10.1111/j.1365-2125.1975.tb02774.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  7. Curzon G., Kantamaneni B. D., Trigwell J. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients. Clin Chim Acta. 1972 Mar;37:335–341. doi: 10.1016/0009-8981(72)90453-6. [DOI] [PubMed] [Google Scholar]
  8. De Silva K. L., Muller P. J., Pearce J. Acute drug-induced extrapyramidal syndromes. Practitioner. 1973 Sep;211(263):316–320. [PubMed] [Google Scholar]
  9. Engberg-Pedersen H. Empirical equation for pharmacokinetic analysis of drug serum levels after oral application. Antimicrob Agents Chemother. 1974 Nov;6(5):554–562. doi: 10.1128/aac.6.5.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gothoni G., Pentikäinen P., Vapaatalo H. I., Hackman R., af Björksten K. Absorption of antibiotics: influence of metoclopramide and atropine on serum levels of pivampicillin and tetracycline. Ann Clin Res. 1972 Aug;4(4):228–232. [PubMed] [Google Scholar]
  11. Howarth F. H., Cockel R., Roper B. W., Hawkins C. F. The effect of metoclopramide upon gastric motility and its value in barium progress meals. Clin Radiol. 1969 Jul;20(3):294–300. doi: 10.1016/s0009-9260(69)80144-3. [DOI] [PubMed] [Google Scholar]
  12. James W. B., Hume R. Action of metoclopramide on gastric emptying and small bowel transit time. Gut. 1968 Apr;9(2):203–205. doi: 10.1136/gut.9.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kuruma I., Bartholini G., Tissot R., Fletscher A. Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats. J Pharm Pharmacol. 1972 Apr;24(4):289–294. doi: 10.1111/j.2042-7158.1972.tb08988.x. [DOI] [PubMed] [Google Scholar]
  14. LEVY G., HAYES B. A. Physicochemical basis of the buffered acetylsalicylic acid controversy. N Engl J Med. 1960 May 26;262:1053–1058. doi: 10.1056/NEJM196005262622102. [DOI] [PubMed] [Google Scholar]
  15. Levy G., Gibaldi M., Procknal J. A. Effect of an anticholinergic agent on riboflavin absorption in man. J Pharm Sci. 1972 May;61(5):798–799. doi: 10.1002/jps.2600610529. [DOI] [PubMed] [Google Scholar]
  16. Marsden C. D., Barry P. E., Parkes J. D., Zilkha K. J. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10–14. doi: 10.1136/jnnp.36.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Matthews D. M., Laster L. Absorption of protein digestion products: a review. Gut. 1965 Oct;6(5):411–426. doi: 10.1136/gut.6.5.411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mearrick P. T., Wade D. N., Birkett D. J., Morris J. Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med. 1974 Apr;4(2):144–148. doi: 10.1111/j.1445-5994.1974.tb03163.x. [DOI] [PubMed] [Google Scholar]
  19. Nimmo J., Heading R. C., Tothill P., Prescott L. F. Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption. Br Med J. 1973 Mar 10;1(5853):587–589. doi: 10.1136/bmj.1.5853.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Malley K., Crooks J., Duke E., Stevenson I. H. Effect of age and sex on human drug metabolism. Br Med J. 1971 Sep 11;3(5775):607–609. doi: 10.1136/bmj.3.5775.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rivera-Calimlim L., Dujovne C. A., Morgan J. P., Lasagna L., Bianchine J. R. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest. 1971 May;1(5):313–320. doi: 10.1111/j.1365-2362.1971.tb00637.x. [DOI] [PubMed] [Google Scholar]
  22. Rivera-Calimlim L., Dujovne C. A., Morgan J. P., Lasagna L., Bianchine J. R. L-dopa treatment failure: explanation and correction. Br Med J. 1970 Oct 10;4(5727):93–94. doi: 10.1136/bmj.4.5727.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rivera-Calimlim L., Morgan J. P., Dujovne C. A., Bianchine J. R., Lasagna L. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol. 1971 Nov;20(11):3051–3057. doi: 10.1016/0006-2952(71)90109-2. [DOI] [PubMed] [Google Scholar]
  24. SHY G. M., DRAGER G. A. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960 May;2:511–527. doi: 10.1001/archneur.1960.03840110025004. [DOI] [PubMed] [Google Scholar]
  25. Sourkes T. L. Dopa decarboxylase: substrates, coenzyme, inhibitors. Pharmacol Rev. 1966 Mar;18(1):53–60. [PubMed] [Google Scholar]
  26. Spencer R. P. Intestinal absorption of amino acids. Current concepts. Am J Clin Nutr. 1969 Mar;22(3):292–299. doi: 10.1093/ajcn/22.3.292. [DOI] [PubMed] [Google Scholar]
  27. Thompson E. N., Williams R. Effect of age on liver function with particular reference to bromsulphalein excretion. Gut. 1965 Jun;6(3):266–269. doi: 10.1136/gut.6.3.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wade D. N., Mearrick P. T., Birkett D. J., Morris J. Variability of L-dopa absorption in man. Aust N Z J Med. 1974 Apr;4(2):138–143. doi: 10.1111/j.1445-5994.1974.tb03162.x. [DOI] [PubMed] [Google Scholar]
  29. Walker J. H., Smith A., Irvine D. Vocational training for general practice: a preliminary report. Br Med J. 1971 Jan 2;1(5739):41–43. doi: 10.1136/bmj.1.5739.41. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES